FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213302810> ?p ?o ?g. }

• W3213302810 endingPage "A534" @default.
• W3213302810 startingPage "A534" @default.
• W3213302810 abstract "Background SO-C101 is a superagonist fusion protein of IL-15 and the IL-15 receptor α sushi+ domain. SO-C101 was investigated in a multicenter, open-label, dose escalation study as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic tumors ( NCT04234113 ). Methods The SO-C101 monotherapy part of the study followed a classical 3+3 dose escalation design. Study objectives were to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D).The evaluation period for dose-limiting toxicities in each dose step was 21 days. The RP2D was defined as MTD or below, also considering pharmacokinetic and pharmacodynamic parameters.The study is ongoing (data cut-off 21 June 2021). Results Thirty patients with a median of 3 (range 1–9) lines of previous systemic therapies were treated at doses 0.25, 0.75, 1.5, 3.0, 6.0., 9.0, 12.0, and 15 µg/kg. At 15 µg/kg, 2 of 3 patients had a dose-limiting toxicity (hyperbilirubinaemia grade [G] 4 and transaminase increase G3). The MTD was reached at 12 µg/kg. This dose was determined as the RP2D, supported by a dose-dependent increase in NK- and CD8+ T cell activation, the latter reaching a plateau at 12 µg/kg. SO-C101 plasma concentration increased dose-proportionally (Tmax was 5.5 hours and T1/2 was 4 hours).The most common adverse events (AEs) were G1 or G2 lymphopenia, local injection site reactions, transaminase increase, flu-like syndrome, and CRS-related symptoms such as fever and chills. Study drug-related AEs >G2 that occurred more than once were lymphopenia and transaminase increase. No treatment-related death was reported.One patient with cutaneous squamous cell carcinoma, who had previously progressed on cemiplimab, showed a partial response at 6.0 µg/kg (duration >4 months, target lesion decrease of 58%). After progression, the patient was put on combination treatment (SO-C101 and pembrolizumab) and again achieved a significant partial response. Two other patients treated with doses below the RP2D had confirmed stable disease for 6 and 15 weeks.At the RP2D, one patient out of 6 discontinued due to progression, while 5 are stable and receiving treatment (range 4–11 weeks). Conclusions The RP2D was defined at 12 µg/kg. SO-C101 administration induced a strong activation of peripheral NK and CD8+ T cells reproducible after each dosing. Related AEs were manageable and resolved quickly. Preliminary clinical efficacy signals including stable disease and partial response were observed in this heavily pretreated patient population. SO-C101 monotherapy has the potential to provide additional clinical benefit to patients with solid tumors. Trial Registration NCT04234113 Ethics Approval This study was approved by the FDA (IND 140011) and by the Ethics Boards of participating institutions." @default.
• W3213302810 created "2021-11-22" @default.
• W3213302810 creator A5005436649 @default.
• W3213302810 creator A5020466887 @default.
• W3213302810 creator A5025270017 @default.
• W3213302810 creator A5037161571 @default.
• W3213302810 creator A5043648997 @default.
• W3213302810 creator A5060793722 @default.
• W3213302810 creator A5061781467 @default.
• W3213302810 creator A5064953304 @default.
• W3213302810 creator A5065206480 @default.
• W3213302810 creator A5071800834 @default.
• W3213302810 creator A5075945805 @default.
• W3213302810 date "2021-11-01" @default.
• W3213302810 modified "2023-10-18" @default.
• W3213302810 title "502 Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors" @default.
• W3213302810 doi "https://doi.org/10.1136/jitc-2021-sitc2021.502" @default.
• W3213302810 hasPublicationYear "2021" @default.
• W3213302810 type Work @default.
• W3213302810 sameAs 3213302810 @default.
• W3213302810 citedByCount "0" @default.
• W3213302810 crossrefType "journal-article" @default.
• W3213302810 hasAuthorship W3213302810A5005436649 @default.
• W3213302810 hasAuthorship W3213302810A5020466887 @default.
• W3213302810 hasAuthorship W3213302810A5025270017 @default.
• W3213302810 hasAuthorship W3213302810A5037161571 @default.
• W3213302810 hasAuthorship W3213302810A5043648997 @default.
• W3213302810 hasAuthorship W3213302810A5060793722 @default.
• W3213302810 hasAuthorship W3213302810A5061781467 @default.
• W3213302810 hasAuthorship W3213302810A5064953304 @default.
• W3213302810 hasAuthorship W3213302810A5065206480 @default.
• W3213302810 hasAuthorship W3213302810A5071800834 @default.
• W3213302810 hasAuthorship W3213302810A5075945805 @default.
• W3213302810 hasBestOaLocation W32133028101 @default.
• W3213302810 hasConcept C111113717 @default.
• W3213302810 hasConcept C112705442 @default.
• W3213302810 hasConcept C126322002 @default.
• W3213302810 hasConcept C143998085 @default.
• W3213302810 hasConcept C181199279 @default.
• W3213302810 hasConcept C185592680 @default.
• W3213302810 hasConcept C197934379 @default.
• W3213302810 hasConcept C2776877979 @default.
• W3213302810 hasConcept C29730261 @default.
• W3213302810 hasConcept C55493867 @default.
• W3213302810 hasConcept C71924100 @default.
• W3213302810 hasConcept C90924648 @default.
• W3213302810 hasConcept C98274493 @default.
• W3213302810 hasConceptScore W3213302810C111113717 @default.
• W3213302810 hasConceptScore W3213302810C112705442 @default.
• W3213302810 hasConceptScore W3213302810C126322002 @default.
• W3213302810 hasConceptScore W3213302810C143998085 @default.
• W3213302810 hasConceptScore W3213302810C181199279 @default.
• W3213302810 hasConceptScore W3213302810C185592680 @default.
• W3213302810 hasConceptScore W3213302810C197934379 @default.
• W3213302810 hasConceptScore W3213302810C2776877979 @default.
• W3213302810 hasConceptScore W3213302810C29730261 @default.
• W3213302810 hasConceptScore W3213302810C55493867 @default.
• W3213302810 hasConceptScore W3213302810C71924100 @default.
• W3213302810 hasConceptScore W3213302810C90924648 @default.
• W3213302810 hasConceptScore W3213302810C98274493 @default.
• W3213302810 hasIssue "Suppl 3" @default.
• W3213302810 hasLocation W32133028101 @default.
• W3213302810 hasOpenAccess W3213302810 @default.
• W3213302810 hasPrimaryLocation W32133028101 @default.
• W3213302810 hasRelatedWork W1758514097 @default.
• W3213302810 hasRelatedWork W1997101420 @default.
• W3213302810 hasRelatedWork W2010116591 @default.
• W3213302810 hasRelatedWork W2090099591 @default.
• W3213302810 hasRelatedWork W2108417615 @default.
• W3213302810 hasRelatedWork W2227061539 @default.
• W3213302810 hasRelatedWork W2410816841 @default.
• W3213302810 hasRelatedWork W2477866235 @default.
• W3213302810 hasRelatedWork W2594910449 @default.
• W3213302810 hasRelatedWork W2992709639 @default.
• W3213302810 hasVolume "9" @default.
• W3213302810 isParatext "false" @default.
• W3213302810 isRetracted "false" @default.
• W3213302810 magId "3213302810" @default.
• W3213302810 workType "article" @default.